Bill > S626

This bill, titled the Prize Fund for HIV/AIDS Act, aims to change how research and development (R&D) incentives are provided for new HIV/AIDS medicines by de-linking them from drug prices and promoting the sharing of scientific knowledge. It establishes a "Prize Fund for HIV/AIDS" to reward innovation in HIV/AIDS treatments and manufacturing processes, rather than relying on market exclusivity, which the bill argues is an expensive and unfair way to incentivize drug development. The bill eliminates exclusive rights to manufacture, distribute, and sell qualifying HIV/AIDS treatments and their manufacturing processes, allowing for more competitive pricing. It also creates a "Donor Innovation Prize Fund" to encourage open competition for low-cost generic drugs in developing countries. The bill outlines eligibility criteria for prize payments, emphasizing factors like patient benefit, therapeutic advantage, and the extent of open sharing of knowledge and technology, and includes provisions for funding through appropriations and an annual fee on health insurance providers.